These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 29125182)

  • 1. Circulating microRNAs as potential biomarkers in myasthenia gravis patients.
    Punga AR; Punga T
    Ann N Y Acad Sci; 2018 Jan; 1412(1):33-40. PubMed ID: 29125182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine.
    Sabre L; Punga T; Punga AR
    Front Immunol; 2020; 11():213. PubMed ID: 32194544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs.
    Fiorillo AA; Heier CR; Huang YF; Tully CB; Punga T; Punga AR
    Front Immunol; 2020; 11():151. PubMed ID: 32153563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
    Punga T; Bartoccioni E; Lewandowska M; Damato V; Evoli A; Punga AR
    J Neuroimmunol; 2016 Mar; 292():21-6. PubMed ID: 26943954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.
    Tan Y; Zhu L; Cui L; Guan Y
    Crit Rev Eukaryot Gene Expr; 2021; 31(2):1-15. PubMed ID: 34347975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.
    Huang X; Zhang Z; Wang Y; Xu M; Du X; Zhang Y
    Neurol Sci; 2023 Nov; 44(11):3877-3884. PubMed ID: 37402938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
    Sabre L; Maddison P; Sadalage G; Ambrose PA; Punga AR
    J Neuroimmunol; 2018 Aug; 321():164-170. PubMed ID: 29804819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients.
    Punga AR; Andersson M; Alimohammadi M; Punga T
    J Neurol Sci; 2015 Sep; 356(1-2):90-6. PubMed ID: 26095457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNA plasma profile in MuSK+ myasthenia gravis.
    Sabre L; Guptill JT; Russo M; Juel VC; Massey JM; Howard JF; Hobson-Webb LD; Punga AR
    J Neuroimmunol; 2018 Dec; 325():87-91. PubMed ID: 30316681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p.
    Beretta F; Huang YF; Punga AR
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
    Sanadze AG; Sidnev DV; Karganov MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small extracellular vesicle microRNAs in pediatric myasthenia gravis plasma and skeletal muscle.
    Zhu M; Wang Y; Xu X; Guo X; Mao Y; Gao F
    Postgrad Med J; 2024 Jun; 100(1185):488-495. PubMed ID: 38449066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of serum miRNA profiles of myasthenia gravis patients.
    Nogales-Gadea G; Ramos-Fransi A; Suárez-Calvet X; Navas M; Rojas-García R; Mosquera JL; Díaz-Manera J; Querol L; Gallardo E; Illa I
    PLoS One; 2014; 9(3):e91927. PubMed ID: 24637658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine.
    Cavalcante P; Mizrachi T; Barzago C; Scandiffio L; Bortone F; Bonanno S; Frangiamore R; Mantegazza R; Bernasconi P; Brenner T; Vaknin-Dembinsky A; Antozzi C
    Pharmacol Res; 2019 Oct; 148():104388. PubMed ID: 31401213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
    Hurst RL; Gooch CL
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
    Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
    J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-30e-5p as predictor of generalization in ocular myasthenia gravis.
    Sabre L; Maddison P; Wong SH; Sadalage G; Ambrose PA; Plant GT; Punga AR
    Ann Clin Transl Neurol; 2019 Feb; 6(2):243-251. PubMed ID: 30847357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
    Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.
    Punga T; Le Panse R; Andersson M; Truffault F; Berrih-Aknin S; Punga AR
    Ann Clin Transl Neurol; 2014 Jan; 1(1):49-58. PubMed ID: 25356381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating miR-23b-3p, miR-145-5p and miR-200b-3p are potential biomarkers to monitor acute pain associated with laminitis in horses.
    Lecchi C; Dalla Costa E; Lebelt D; Ferrante V; Canali E; Ceciliani F; Stucke D; Minero M
    Animal; 2018 Feb; 12(2):366-375. PubMed ID: 28689512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.